MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion worldwide dermatology and skin care market.
Founded in 2015, the company is developing rational microbiome therapies based on Dr. Richard L. Gallo’s basic and clinical research for the top 5 dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and Skin Infections, which have a huge impact on patients’ quality of life. More than 230 million patients suffer from these 5 skin diseases.
Good Bacteria Help Prevent Skin Diseases by Fighting Bad Bacteria
MatriSys Bio’s scientific approach is to rebalance the natural skin microbiome by application of microbial therapies -“Good Bugs” that selectively target skin pathogens -“Bad Bugs”. Our lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis (“AD”) market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. Our “Good Bug”, S. hominis, is highly potent against the “Bad Bug”, Staph. aureus, which has long been associated with AD. S. hominis does not affect other “Good Bugs” leading to the natural rebalance of the skin microbiome.
MatriSys Bioscience’s Solution is to Re-Balance Skin Health by Integrating the Skin Microbiome and the Innate Immune System
Our Intellectual Property offers multiple routes for commercialization: Rx Dermatology, Skin Care, and Cosmetic. Licensing discussions are currently underway for our first asset, S. hominis.
MatriSys Bio’s lead project MSB-01 is a novel, highly selective topical antimicrobial “Live Biotherapeutic Product” that replaces the bacteria deficient on the skin of Atopic Dermatitis patients that are needed for host defense.
Cosmetic and Skin Care Applications
To add value to the company in the cosmetic and skin care market, MatriSys Bio is developing novel cosmetic ingredients from the fermentation of its IP protected bacterial strains.
February 1, 2015
Cell Host & Microbe: S. epidermidis Influence on Host Immunity: More Than Skin Deep – Richard L. Gallopdf
January 1, 2015
Science: Dermal adipocytes protect against invasive Staphylococcus aureus skin infection - Ling-juan Zhang, Christian F. Guerrero-Juarez, Tissa Hata, Sagar P. Bapat, Raul Ramos, Maksim V. Plikus and Richard L. Gallopdf
December 1, 2013
Trends in Microbiology: Structure and function of the human skin microbiome - Nina N. Schommer and Richard L. Gallopdf
November 1, 2013
Seminars in Immunology: Functions of the skin microbiota in health and disease - James A. Sanford and Richard L. Gallopdf
February 1, 2013
Nature Communications: The microbiome extends to subepidermal compartments of normal skin - Teruaki Nakatsuji, Hsin-I. Chiang, Shangi B. Jiang, Harish Nagarajan, Karsten Zengler and Richard L. Gallopdf
- January 1, 2011 pdf
December 1, 2009
Nature Medicine: Commensal bacteria regulate Toll-like receptor 3–dependent inflammation after skin injury - Yuping Lai, Anna Di Nardo, Teruaki Nakatsuji, Anke Leichtle, Yan Yang, Anna L Cogen, Zi-Rong Wu, Lora V Hooper, Richard R Schmidt, Sonja von Aulock, Katherine A Radek, Chun-Ming Huang, Allen F Ryan and Richard L Gallopdf
February 1, 2009
Trends in Immunology: AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense - Yuping Lai and Richard L. Gallopdf
March 1, 2008
NIH Public Access: Skin microbiota: a source of disease or defence? - A.L. Cogen, V. Nizet and R.L. Gallopdf
Professor Richard L. Gallo
UCSD Dermatology Professor Richard L. Gallo MD, PhD is a world leader in the use of microbes as novel medicines. He is a co-founder and head of MatriSys Bio’s Scientific Advisory Board. His work has focused on host defense and mutualistic interactions with microbes on the skin, with a particular interest in antimicrobial peptides and the basic functions of the skin microbiome.
Professor Richard L. Gallo
UCSD Dermatology Professor Richard L. Gallo MD, PhD is a world leader in the use of microbes as novel medicines. He is a co-founder and head of MatriSys Bio’s Scientific Advisory Board. His work has focused on host defense and mutualistic interactions with microbes on the skin, with a particular interest in antimicrobial peptides and the basic functions of the skin microbiome. Through high-throughput functional screening of the normal human skin microbiome, Dr. Gallo has identified specific strains of commensal Staphylococcus species that kill pathogenic bacteria and enhance skin innate immune defense. One of those common and beneficial commensals on human skin, S. hominis Sh-A9 was shown by UCSD researchers to produce lantibiotic peptides that display specific, potent antimicrobial activity towards Staphylococcus aureus, the pathogen associated with Atopic Dermatitis persistence. The company’s collaboration with the Gallo Laboratory at UCSD has resulted in the establishment of MatriSys Bioscience’s broad patent position to develop numerous therapeutics for large patient populations.